To include your compound in the COVID-19 Resource Center, submit it here.

Innate reports additional Phase I data for IPH4102 in cutaneous T cell lymphoma (CTCL)

In October, Innate Pharma S.A. (Euronext:IPH) reported additional data from the dose escalation portion of the Phase I IPH4102-101 trial. Among 20 patients with relapsed or refractory Sezary syndrome

Read the full 297 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE